News & Events about Cormedix Inc.
BERKELEY HEIGHTS, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that the United States ...
Latest Ratings for CRMD
DateFirmActionFromTo May 2021NeedhamMaintainsBuy Feb 2021NeedhamInitiates Coverage OnBuy Feb 2021Truist SecuritiesMaintainsBuy
View More Analyst Ratings for CRMD
View the Latest Analyst Ratings
read more...
Globe Newswire
2 months ago
BERKELEY HEIGHTS, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that it will report its ...
Needham Company LLC reissued their buy rating on shares of CorMedix (NASDAQ:CRMD Get Rating) in a research report report published on Friday morning, Benzinga reports. Needham Company LLC currently has a $13.00 price target on the stock. Separately, JMP Securities lifted their ...
Globe Newswire
4 months ago
BERKELEY HEIGHTS, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the following promotions ...